Short answer
Bioventus Inc. (BVS) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 27, 2026. Quarterly revenue was $153M (up 3.8% year over year) with net income of $33M.
Q2 2026 key financials · XBRL
- Revenue
- $153M
- +3.8% YoY · +16.0% QoQ
- Net income
- $33M
- +348.3% YoY · +974.2% QoQ
- Operating margin
- 12.5%
- Gross margin
- 69.0%
- EPS (diluted)
- $0.48
- +336.4% YoY · +1100.0% QoQ
Source: XBRL data from the Bioventus Inc. (BVS) Q2 2026 10-Q on SEC EDGAR. USD.
Bioventus Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $153.2M, up $5.5M or 3.8% YoY
- Operating margin 12.5% vs 12.4%; gross margin 69.0% vs 69.1% YoY
- Best performer U.S. Pain Treatments, revenue $72.7M, up 12.8%; worst Surgical Solutions, down 4.7% to $43.6M
- $20.0M discretionary term-loan prepayment; $98.4M revolver capacity available
- Strategic alternatives review underway; no timetable or transaction assurance disclosed
Risk Factors
- New strategic-alternatives review risk triggered by August 2026 unsolicited acquisition proposal and other indications of interest
- Transaction uncertainty risk, including possible failure to complete a deal due to regulatory approvals, market conditions, or financing availability
- Operational disruption risk from time-consuming review activities, distraction, and potential loss of business opportunities
- Legal risk from potentially costly and time-consuming litigation related to the strategic-alternatives process
- Market risk from speculation, with potential significant common-stock price fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bioventus Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.